289 related articles for article (PubMed ID: 12127376)
1. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
Atalar E; Ozmen F; Haznedaroglu I; Açil T; Ozer N; Ovünç K; Aksöyek S; Kes S
Int J Cardiol; 2002 Aug; 84(2-3):227-31. PubMed ID: 12127376
[TBL] [Abstract][Full Text] [Related]
2. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
Xu RX; Guo YL; Li XL; Li S; Li JJ
Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):475-81. PubMed ID: 24739131
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.
Oka H; Ikeda S; Koga S; Miyahara Y; Kohno S
Heart Vessels; 2008 Jul; 23(4):249-56. PubMed ID: 18649055
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
6. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
Orem C; Uydu HA; Yilmaz R; Gökçe M; Baykan M; Eminagaoglu S; Orem A
Jpn Heart J; 2004 Nov; 45(6):977-87. PubMed ID: 15655273
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Pontrelli L; Parris W; Adeli K; Cheung RC
Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
[TBL] [Abstract][Full Text] [Related]
9. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
10. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
[TBL] [Abstract][Full Text] [Related]
11. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
Kuryata OV; Yegorova YV
Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
[TBL] [Abstract][Full Text] [Related]
12. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
[TBL] [Abstract][Full Text] [Related]
14. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
Romero R; Calviño J; Rodriguez J; Sánchez-Guisande D
Nephrol Dial Transplant; 2000 Sep; 15(9):1446-9. PubMed ID: 10978406
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
Aguilar-Salinas CA; Gómez-Pérez FJ; Posadas-Romero C; Vázquez-Chávez C; Meaney E; Gulías-Herrero A; Guillén LE; Alvarado Vega A; Mendoza Pérez E; Eduardo Romero-Nava L; Angélica Gómez-Díaz R; Salinas-Orozco S; Moguel R; Novoa G
Atherosclerosis; 2000 Oct; 152(2):489-96. PubMed ID: 10998478
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
[TBL] [Abstract][Full Text] [Related]
18. Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
Jurukovska-Nospal M; Arsova V; Levchanska J; Sidovska-Ivanovska B
Prilozi; 2007 Dec; 28(2):137-48. PubMed ID: 18356785
[TBL] [Abstract][Full Text] [Related]
19. No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin.
Singhal MK; Bhaskaran S; Szabo T; La Rosa R
Perit Dial Int; 1999; 19(1):89-91. PubMed ID: 10201354
[No Abstract] [Full Text] [Related]
20. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
Kural BV; Orem C; Uydu HA; Alver A; Orem A
Coron Artery Dis; 2004 Aug; 15(5):277-83. PubMed ID: 15238825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
